Meeting
2014 ASCO Annual Meeting
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.
Authors
Pooja Prem Advani
Mayo Clinic, Jacksonville, FL
Pooja Prem Advani , Karla V. Ballman , Travis J. Dockter , Gerardo Colon-Otero , Edith A. Perez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 603)
DOI
10.1200/jco.2014.32.15_suppl.603
Abstract #
603
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer.
First Author: Rui Wang
Poster
2013 Breast Cancer Symposium
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
First Author: Neil M. Iyengar
Poster
2013 ASCO Annual Meeting
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
First Author: Patrick Glyn Morris
Poster
2011 ASCO Annual Meeting
Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
First Author: C. T. Dang